Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fracture healing compound enters trials:

This article was originally published in Clinica

Executive Summary

Orthopaedic device manufacturer OrthoLogic has begun enrolling patients in a trial of a compound for speeding up fracture healing. The double-blind Phase I/II study of 90 patients will evaluate the safety and preliminary efficacy of Chrysalin, a synthetic peptide, which is injected at the fracture site. Tempe, Arizona-based OrthoLogic has acquired an equity stake in start-up biotech firm Chrysalis BioTechnology, based in Galveston, Texas.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT073046

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel